Lung Cancer

What did the PRONOUNCE trial assess in NSCLC ?
irst-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer

en_USEnglish